CY1112478T1 - Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες - Google Patents
Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντεςInfo
- Publication number
- CY1112478T1 CY1112478T1 CY20121100255T CY121100255T CY1112478T1 CY 1112478 T1 CY1112478 T1 CY 1112478T1 CY 20121100255 T CY20121100255 T CY 20121100255T CY 121100255 T CY121100255 T CY 121100255T CY 1112478 T1 CY1112478 T1 CY 1112478T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- kinazolinone
- cancer factors
- quinazolinone compounds
- alone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Ενώσεις κιναζολινόνης, φαρμακευτικώς αποδεκτά άλατα και προφάρμακα αυτών, συνθέσεις που περιλαμβάνουν φαρμακευτικώς αποδεκτό φορέα και μία ή περισσότερες από τις ενώσεις κιναζολινόνης, είτε μόνες είτε σε συνδυασμό με τουλάχιστον έναν επιπρόσθετο θεραπευτικό παράγοντα. Μέθοδοι χρήσης των ενώσεων κιναζολινόνης, είτε μόνων είτε σε συνδυασμό με τουλάχιστον έναν επιπρόσθετο θεραπευτικό παράγοντα ως αναστολείς ΚSΡ, στην προφύλαξη ή τη θεραπεία πολλαπλασιαστικών ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52505903P | 2003-11-25 | 2003-11-25 | |
EP04812051A EP1689724B1 (en) | 2003-11-25 | 2004-11-24 | Quinazolinone compounds as anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112478T1 true CY1112478T1 (el) | 2015-12-09 |
Family
ID=34632957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100255T CY1112478T1 (el) | 2003-11-25 | 2012-03-12 | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες |
Country Status (17)
Country | Link |
---|---|
US (2) | US7939539B2 (el) |
EP (1) | EP1689724B1 (el) |
JP (2) | JP4778439B2 (el) |
KR (1) | KR20060127413A (el) |
CN (1) | CN1886384A (el) |
AT (1) | ATE538103T1 (el) |
AU (1) | AU2004293464A1 (el) |
CA (1) | CA2546932A1 (el) |
CY (1) | CY1112478T1 (el) |
DK (1) | DK1689724T3 (el) |
ES (1) | ES2376552T3 (el) |
IL (1) | IL175714A0 (el) |
PL (1) | PL1689724T3 (el) |
PT (1) | PT1689724E (el) |
SG (1) | SG148202A1 (el) |
SI (1) | SI1689724T1 (el) |
WO (1) | WO2005051922A1 (el) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7671200B2 (en) | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
AU2003213092A1 (en) * | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
JP2005530785A (ja) * | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
EP1558083A4 (en) * | 2002-09-30 | 2008-04-16 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
NZ551004A (en) | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
CA2575188A1 (en) | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
US20070207996A1 (en) * | 2004-08-30 | 2007-09-06 | Auger Kurt R | Novel Compositions And Methods Of Treatment |
US20080064680A1 (en) * | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
JP2010510224A (ja) | 2006-11-17 | 2010-04-02 | アボット・ラボラトリーズ | ケモカイン受容体拮抗薬としてのアミノピロリジン類 |
KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
CA2714087A1 (en) * | 2008-02-14 | 2009-08-20 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
CN101250189B (zh) * | 2008-03-25 | 2010-06-16 | 中山大学 | 双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CN101857595B (zh) * | 2010-05-21 | 2012-11-21 | 中山大学 | 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途 |
CN101899009B (zh) * | 2010-07-30 | 2012-04-04 | 江苏昊华精细化工有限公司 | 医药中间体4(h)喹唑酮的制造方法 |
CN101967127B (zh) * | 2010-09-28 | 2013-05-29 | 中山大学 | 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用 |
DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
CN103012291B (zh) * | 2012-12-17 | 2014-09-03 | 中山大学 | 一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用 |
NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
CA2895782C (en) * | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
KR20160012194A (ko) | 2013-05-27 | 2016-02-02 | 노파르티스 아게 | 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도 |
PL3004112T3 (pl) | 2013-05-28 | 2018-02-28 | Novartis Ag | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby |
EP3004108B1 (en) | 2013-05-28 | 2017-10-18 | Novartis AG | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
PL3008053T3 (pl) | 2013-06-14 | 2018-08-31 | Gilead Calistoga Llc | Inhibitory 3-kinazy fosfatydyloinozytolu |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2016004340A (es) | 2013-10-04 | 2016-08-08 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
CN105916857B (zh) | 2013-11-21 | 2018-06-22 | 诺华股份有限公司 | 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途 |
US10022453B2 (en) | 2013-12-23 | 2018-07-17 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
PT3119397T (pt) | 2014-03-19 | 2022-04-11 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10485880B2 (en) | 2014-12-15 | 2019-11-26 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies |
MX2017017172A (es) | 2015-06-22 | 2018-02-23 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
JP6905941B2 (ja) | 2015-06-23 | 2021-07-21 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体 |
CN107921145A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物(adc) |
EP3317277B1 (en) | 2015-07-01 | 2021-01-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
BR112019012883A2 (pt) | 2016-12-21 | 2019-11-26 | Bayer Ag | conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis |
CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
SG11202012608VA (en) | 2018-06-18 | 2021-02-25 | Bayer Ag | Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
CN111499634B (zh) * | 2019-01-31 | 2023-05-12 | 贝达药业股份有限公司 | 一种喹唑啉化合物及其在医药上的应用 |
MX2022004739A (es) | 2019-10-31 | 2022-07-19 | Holosmedic | Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo. |
KR102682775B1 (ko) | 2020-06-26 | 2024-07-08 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
WO2022231377A1 (ko) | 2021-04-29 | 2022-11-03 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 및 그의 용도 |
KR20240084923A (ko) * | 2022-12-07 | 2024-06-14 | 부산대학교 산학협력단 | 신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4329418A1 (de) * | 1993-09-01 | 1995-03-02 | Agfa Gevaert Ag | Gelbkuppler |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
NZ518480A (en) * | 1999-10-27 | 2004-02-27 | Cytokinetics Inc | Methods and compositions utilizing quinazolinones |
JP2002296741A (ja) | 2001-03-30 | 2002-10-09 | Fuji Photo Film Co Ltd | 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物 |
JP4267838B2 (ja) | 2001-03-30 | 2009-05-27 | 富士フイルム株式会社 | 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物 |
US6677110B2 (en) * | 2001-03-30 | 2004-01-13 | Fuji Photo Film Co., Ltd. | Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound |
JP2002318442A (ja) | 2001-04-20 | 2002-10-31 | Fuji Photo Film Co Ltd | 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物 |
JP4267840B2 (ja) | 2001-04-20 | 2009-05-27 | 富士フイルム株式会社 | 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物 |
AU2002363429B2 (en) | 2001-11-07 | 2008-05-08 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
DE60222302T2 (de) | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
JP2005530785A (ja) | 2002-05-09 | 2005-10-13 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、及び方法 |
US7038048B2 (en) | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
EP1517904A4 (en) | 2002-05-23 | 2007-02-21 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESIN |
US20040048853A1 (en) | 2002-08-21 | 2004-03-11 | Gustave Bergnes | Compounds, compositions, and methods |
EP1558083A4 (en) | 2002-09-30 | 2008-04-16 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
-
2004
- 2004-11-24 CA CA002546932A patent/CA2546932A1/en not_active Abandoned
- 2004-11-24 KR KR1020067012603A patent/KR20060127413A/ko not_active Application Discontinuation
- 2004-11-24 AU AU2004293464A patent/AU2004293464A1/en not_active Abandoned
- 2004-11-24 JP JP2006541684A patent/JP4778439B2/ja not_active Expired - Fee Related
- 2004-11-24 SI SI200431833T patent/SI1689724T1/sl unknown
- 2004-11-24 PL PL04812051T patent/PL1689724T3/pl unknown
- 2004-11-24 CN CNA2004800348103A patent/CN1886384A/zh active Pending
- 2004-11-24 SG SG200808730-6A patent/SG148202A1/en unknown
- 2004-11-24 ES ES04812051T patent/ES2376552T3/es active Active
- 2004-11-24 PT PT04812051T patent/PT1689724E/pt unknown
- 2004-11-24 AT AT04812051T patent/ATE538103T1/de active
- 2004-11-24 US US10/996,814 patent/US7939539B2/en not_active Expired - Fee Related
- 2004-11-24 WO PCT/US2004/039448 patent/WO2005051922A1/en active Application Filing
- 2004-11-24 EP EP04812051A patent/EP1689724B1/en not_active Not-in-force
- 2004-11-24 DK DK04812051.3T patent/DK1689724T3/da active
-
2006
- 2006-05-17 IL IL175714A patent/IL175714A0/en unknown
-
2010
- 2010-12-21 JP JP2010285141A patent/JP2011084570A/ja not_active Withdrawn
-
2011
- 2011-04-12 US US13/085,048 patent/US20110190293A1/en not_active Abandoned
-
2012
- 2012-03-12 CY CY20121100255T patent/CY1112478T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL175714A0 (en) | 2006-09-05 |
AU2004293464A1 (en) | 2005-06-09 |
CN1886384A (zh) | 2006-12-27 |
US20110190293A1 (en) | 2011-08-04 |
WO2005051922A1 (en) | 2005-06-09 |
DK1689724T3 (da) | 2012-02-27 |
JP2007512368A (ja) | 2007-05-17 |
SG148202A1 (en) | 2008-12-31 |
EP1689724B1 (en) | 2011-12-21 |
ES2376552T3 (es) | 2012-03-14 |
SI1689724T1 (sl) | 2012-04-30 |
CA2546932A1 (en) | 2005-06-09 |
US7939539B2 (en) | 2011-05-10 |
JP4778439B2 (ja) | 2011-09-21 |
KR20060127413A (ko) | 2006-12-12 |
EP1689724A1 (en) | 2006-08-16 |
PT1689724E (pt) | 2012-02-06 |
US20050209254A1 (en) | 2005-09-22 |
PL1689724T3 (pl) | 2012-05-31 |
JP2011084570A (ja) | 2011-04-28 |
ATE538103T1 (de) | 2012-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
TW200505454A (en) | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
DE602004025698D1 (de) | PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS | |
WO2004006859A3 (en) | Platinum compound | |
TW200728304A (en) | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | |
NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
TW200716628A (en) | Novel compounds | |
GEP20125691B (en) | Compounds and compositions as protein kinase inhibitors | |
BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
BRPI0414082A (pt) | formas de dosagem de liberação sustentada de ziprasidona | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
PT2383271E (pt) | Aminoquinolonas como inibidores de gsk-3 | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2005004808A3 (en) | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | |
SE0401342D0 (sv) | Therapeutic compounds | |
ATE477805T1 (de) | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität | |
HK1121936A1 (en) | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | |
TW200732304A (en) | Piperidine derivatives | |
WO2006102375A3 (en) | Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer | |
UA93522C2 (en) | 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones | |
ATE429435T1 (de) | 7h-pyrrolopyrimidinderivate | |
MX2010004314A (es) | Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso. |